CRANBURY, N.J. - Palatin Technologies (NYSE:PTN), Inc. (NYSE American: PTN), a biopharmaceutical company, today announced progress in its clinical development programs and outlined anticipated milestones for the coming year. The company is advancing studies across several therapeutic areas including dry eye disease, obesity, male sexual dysfunction, and ulcerative colitis.
In the realm of ocular treatments, Palatin has concluded a positive Type C meeting with the FDA for its Phase 3 PL9643 clinical program for dry eye disease (DED), with agreements on trial protocols and endpoints. Patient enrollment for the MELODY-2 and MELODY-3 pivotal clinical studies is targeted to begin in the fourth quarter of 2024, with topline results expected in the same period of 2025.
For obesity treatment, Palatin has initiated patient dosing in a Phase 2 clinical study combining a melanocortin agonist bremelanotide (MC4R) with tirzepatide (GLP-1). The primary goal is to evaluate the safety and efficacy of this combination in reducing body weight, with results anticipated in the first half of 2025.
The company is also developing a treatment for erectile dysfunction (ED) in patients who do not respond to PDE5 inhibitor monotherapy. A pharmacokinetics study for bremelanotide co-formulated with a PDE5 inhibitor is slated to start in the first quarter of 2025, with Phase 3 patient recruitment expected in the second half of the same year.
Palatin's ulcerative colitis program is progressing with an oral PL8177 formulation, with an interim analysis readout expected in the fourth quarter of 2024 and topline results anticipated in the first quarter of 2025.
The company has also completed the sale of its asset Vyleesi, a bremelanotide injection for hypoactive sexual desire disorder, to Cosette Pharmaceuticals for up to $171 million, retaining rights for its use in obesity and male erectile dysfunction indications.
Palatin's strategy involves the development of melanocortin receptor agonists, a class of molecules that modulate the activity of the melanocortin receptor system, which plays a role in various physiological functions. The company seeks to develop first-in-class medicines for diseases with significant unmet medical need and commercial potential.
The information in this article is based on a press release statement from Palatin Technologies.
In other recent news, Palatin Technologies has been actively advancing its clinical development programs. The company has announced key dates for its upcoming annual meeting of stockholders and opened proposals for shareholder consideration. H.C. Wainwright has maintained its Buy rating for Palatin, following the commencement of several clinical trials, including a Phase II trial for a potential obesity treatment combining Bremelanotide with Tirzepatide.
The company has also made significant strides with the FDA's approval of its Phase 3 clinical trial protocols for its dry eye disease treatment, PL9643. Furthermore, Palatin is preparing to submit an Investigational New Drug application for a new co-formulation combining bremelanotide with a PDE5i, with a potential Phase 3 clinical trial projected to begin in the first half of 2025.
In terms of financials, Palatin's Q3 fiscal year 2024 results showed a net loss of $8.4 million, largely due to investments in Melanocortin receptor programs. However, the company has secured approximately $6.1 million from the exercise of warrants, which will be allocated for working capital and other corporate purposes.
These recent developments highlight Palatin's commitment to advancing its clinical programs and engaging with regulatory authorities, while maintaining a focus on corporate governance and shareholder engagement.
InvestingPro Insights
Amidst its clinical development milestones, Palatin Technologies, Inc. (NYSE American: PTN) faces a challenging financial landscape, according to the latest data from InvestingPro. The company's market capitalization stands at a modest $28.67 million, reflecting investor sentiment and market recognition of its size and potential. While Palatin has been advancing in its clinical programs, it's important to note that the company is trading at a high Price / Book multiple of 18.16, which suggests that the stock might be overvalued relative to its net assets.
InvestingPro data also reveals a significant revenue growth of 52.8% in the last twelve months as of Q3 2024, indicating that despite some operational challenges, the company is managing to increase its sales. However, this growth comes with a caveat; Palatin has reported a negative gross profit margin of -329.27%, highlighting inefficiencies or high costs relative to its revenues. This is corroborated by an InvestingPro Tip pointing out the company's weak gross profit margins.
Palatin's financial health is a mix of strengths and vulnerabilities. One of the InvestingPro Tips notes that the company holds more cash than debt on its balance sheet, which is typically a positive indicator of financial stability. On the flip side, Palatin is quickly burning through cash and analysts have revised their earnings downwards for the upcoming period, suggesting that the company may face liquidity challenges and potential downward pressure on its stock price.
For investors seeking more comprehensive analysis, there are additional InvestingPro Tips available that delve into other facets of Palatin's financial and operational performance. These tips provide valuable insights for those looking to make an informed decision about investing in the company.
For a deeper dive into Palatin Technologies' financial metrics and to access exclusive market insights, visit https://www.investing.com/pro/PTN
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.